Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial.

Abou-Alfa, Ghassan K.Meyer, TimCheng, Ann-LiiEl-Khoueiry, AnthonyRimassa, LorenzaRyoo, Baek-YeolCicin, Irfan2024-06-122024-06-1220180732-183X1527-7755https://doi.org/10.1200/JCO.2018.36.15_suppl.4019https://hdl.handle.net/20.500.14551/25934[Abstract Not Available]en10.1200/JCO.2018.36.15_suppl.4019info:eu-repo/semantics/closedAccess[No Keywords]Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial.Conference Object3615Q1WOS:000442916001596